462 related articles for article (PubMed ID: 27430559)
1. How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study.
Belger M; Haro JM; Reed C; Happich M; Kahle-Wrobleski K; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
BMC Med Res Methodol; 2016 Jul; 16():83. PubMed ID: 27430559
[TBL] [Abstract][Full Text] [Related]
2. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
[TBL] [Abstract][Full Text] [Related]
3. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
[TBL] [Abstract][Full Text] [Related]
4. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
[TBL] [Abstract][Full Text] [Related]
5. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
[TBL] [Abstract][Full Text] [Related]
6. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
[TBL] [Abstract][Full Text] [Related]
7. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
[TBL] [Abstract][Full Text] [Related]
8. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
[TBL] [Abstract][Full Text] [Related]
9. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
[TBL] [Abstract][Full Text] [Related]
10. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
[TBL] [Abstract][Full Text] [Related]
12. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
[TBL] [Abstract][Full Text] [Related]
13. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
[TBL] [Abstract][Full Text] [Related]
14. Consequences of Anosognosia on the Cost of Caregivers' Care in Alzheimer's Disease.
Turró-Garriga O; Garre-Olmo J; Reñé-Ramírez R; Calvó-Perxas L; Gascón-Bayarri J; Conde-Sala JL
J Alzheimers Dis; 2016 Oct; 54(4):1551-1560. PubMed ID: 27636844
[TBL] [Abstract][Full Text] [Related]
15. What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.
Reed C; Happich M; Argimon JM; Haro JM; Wimo A; Bruno G; Dodel R; Jones RW; Vellas B; Belger M
J Alzheimers Dis; 2017; 57(3):797-812. PubMed ID: 28304285
[TBL] [Abstract][Full Text] [Related]
16. Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours.
Haro JM; Kahle-Wrobleski K; Bruno G; Belger M; Dell'Agnello G; Dodel R; Jones RW; Reed CC; Vellas B; Wimo A; Argimon JM
J Nutr Health Aging; 2014 Jul; 18(7):677-84. PubMed ID: 25226106
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
[TBL] [Abstract][Full Text] [Related]
18. Heckman imputation models for binary or continuous MNAR outcomes and MAR predictors.
Galimard JE; Chevret S; Curis E; Resche-Rigon M
BMC Med Res Methodol; 2018 Aug; 18(1):90. PubMed ID: 30170561
[TBL] [Abstract][Full Text] [Related]
19. Multiple imputation methods for handling missing data in cost-effectiveness analyses that use data from hierarchical studies: an application to cluster randomized trials.
Gomes M; Díaz-Ordaz K; Grieve R; Kenward MG
Med Decis Making; 2013 Nov; 33(8):1051-63. PubMed ID: 23913915
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of full costs of care for patients with Alzheimer's disease in France: the predominant role of informal care.
Gervès C; Chauvin P; Bellanger MM
Health Policy; 2014 May; 116(1):114-22. PubMed ID: 24461717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
